Resistance factors in advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers found that Abbylon acetate/prednisone is the standard treatment for progressive, incurable, and castration-resistant prostate cancer, resulting in key genomic changes
in patient responses.

"We have defined a potential strategy for both drug responders and non-responders that could help patients overcome drug resistance and extend time to survival," said
Liewei Wang, MD, director of the Mayo Clinical Center's Pharmacogenomics Program Bernard and Edith Waterman.

Dr.

Abiraterone acetate is the standard treatment option
for castration-resistant prostate cancer in men.

In the Prostate Cancer Medicine-Optimized Genome Enhancement Therapy study, Mayo researchers revealed DNA sequences associated with the abiraterone acetate response to identify other treatment options
for patients with advanced prostate cancer who are resistant to all standard therapies.

In the next analysis of this prospective study, the researchers analyzed total exome sequencing and RNA sequence data
from 83 patients with metastatic biopsy before and after 12 weeks of treatment with abiraterone acetate/prednisone.

"We analyzed the post-treatment genomic profile of metastatic biopsy in these patients with metastatic castration-resistant prostate cancer to determine the mechanism of acquired drug resistance," said
Dr.

Dr.

Dr Sicotte said: "Further research is needed to test whether these drug treatments overcome abirodone acetate/prednisone resistance and identify subgroups
that did not respond.

In the United States, prostate cancer is the most common malignant of solid organs, with more than 268,490 new diagnoses and an estimated 34,500 deaths
each year.

The PROMOTE study is a collaborative project
between the Mayo Clinic Personalized Medicine Center and the Mayo Clinic Comprehensive Cancer Center.

Journal Reference:

1. Hugues Sicotte, Krishna R.